DRG Market Assessment 보고서

The chronic obstructive pulmonary disease (COPD) market continues to gradually shift away from LABA/ICS FDCs toward LABA/LAMA FDCs and LABA/LAMA/ICS FDCs, but current and emerging generics are…

Age-related macular degeneration (AMD) is a late-onset retinal disease that diminishes central visual acuity due to photoreceptor degeneration in the macula, leading to vision impairment and…

Immune checkpoint inhibitors continue to anchor the treatment of non-small-cell lung cancer (NSCLC), while rapid advances in biomarker-driven strategies are accelerating patient segmentation and…

Wet AMD (age-related macular degeneration) is a leading cause of vision loss among older adults, with significant implications on patient’s independence and quality of life. The treatment…

Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors, such as Johnson & Johnson…

Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…

Generalized onset seizures (GOS) originate simultaneously in both hemispheres of the brain and account for nearly 40% of all epilepsy cases. Current management relies primarily on widely used…

Painful diabetic neuropathy (PDN) is a prevalent complication of chronic diabetes, inducing enduring and often intense pain, characterized by sensations of burning, stabbing, tingling, and…

The angiogenesis inhibitor Erbitux, in combination with platinum-based therapy and 5-fluorouracil (5-FU), was the standard treatment option for all squamous cell carcinoma of the head and neck (…

Driven by DRG’s oncology expertise and real-world data capabilities, the Real World Brand Tracker is an interactive dashboard of regularly updated U.S. claims data that monitors and highlights…

The non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL) therapy market is rapidly evolving as novel agents provide alternatives to conventional chemoimmunotherapy regimens. This…

The treatment of multiple myeloma is becoming increasingly complex. Sanofi’s Sarclisa received a label expansion for the first-line treatment of autologous stem-cell transplantation-ineligible…